CTI BioPharma (CTIC) PT Raised to $5.90 at Stifel with a Buy Rating, Analyst Sees Broadening Commercial Opportunity for VONJO
Tweet Send to a Friend
Stifel analyst Benjamin Burnett raised the price target on CTI BioPharma (NASDAQ: CTIC) to $5.90 (from $5.40) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
